A Dose-ranging Study With Brivaracetam in Patients From 16 to 65 Years With Refractory Partial Onset Seizures.
NCT00175825
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
210
Enrollment
INDUSTRY
Sponsor class
Conditions
Epilepsy
Interventions
OTHER:
Placebo
DRUG:
Brivaracetam
Sponsor
UCB Pharma